THE MEDICAL NEWS

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and NHG Health's Institute of Mental Health (IMH) have mapped how brain networks differ in individuals at Clinical High Risk (CHR) for psychosis, providing a new perspective on the mechanisms underlying the disease onset.

EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to advance its lead program EPY201 through Phase 1/2a clinical trials.

VALANX Biotech (VALANX), a biotech company developing novel antibody-drug-conjugate (ADC) assets enabled by its GoldenSite™ site-specific protein conjugation technology, today announced the formation of its Board of Directors.

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new tri…

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

By analysing nationally representative diet data, researchers show that food additives rarely occur alone, with children and teenagers experiencing the highest exposure to complex additive mixtures largely driven by ultra-processed foods.

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.